GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Akoya Biosciences Inc (NAS:AKYA) » Definitions » Scaled Net Operating Assets

AKYA (Akoya Biosciences) Scaled Net Operating Assets : 0.40 (As of Jun. 2024)


View and export this data going back to 2021. Start your Free Trial

What is Akoya Biosciences Scaled Net Operating Assets?

Scaled Net Operating Assets (SNOA) is calculated as the difference between operating assets and operating liabilities, scaled by lagged total assets.

Akoya Biosciences's operating assets for the quarter that ended in Jun. 2024 was $98.52 Mil. Akoya Biosciences's operating liabilities for the quarter that ended in Jun. 2024 was $36.80 Mil. Akoya Biosciences's Total Assets for the quarter that ended in Mar. 2024 was $154.75 Mil. Therefore, Akoya Biosciences's scaled net operating assets (SNOA) for the quarter that ended in Jun. 2024 was 0.40.


Akoya Biosciences Scaled Net Operating Assets Historical Data

The historical data trend for Akoya Biosciences's Scaled Net Operating Assets can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Akoya Biosciences Scaled Net Operating Assets Chart

Akoya Biosciences Annual Data
Trend Dec19 Dec20 Dec21 Dec22 Dec23
Scaled Net Operating Assets
-0.30 -0.37 0.53 0.28 0.32

Akoya Biosciences Quarterly Data
Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24
Scaled Net Operating Assets Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.35 0.31 0.32 0.31 0.40

Competitive Comparison of Akoya Biosciences's Scaled Net Operating Assets

For the Medical Instruments & Supplies subindustry, Akoya Biosciences's Scaled Net Operating Assets, along with its competitors' market caps and Scaled Net Operating Assets data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Akoya Biosciences's Scaled Net Operating Assets Distribution in the Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, Akoya Biosciences's Scaled Net Operating Assets distribution charts can be found below:

* The bar in red indicates where Akoya Biosciences's Scaled Net Operating Assets falls into.



Akoya Biosciences Scaled Net Operating Assets Calculation

Scaled Net Operating Assets (SNOA) is calculated as the difference between operating assets and operating liabilities, scaled by lagged total assets.

Akoya Biosciences's Scaled Net Operating Assets (SNOA) for the fiscal year that ended in Dec. 2023 is calculated as

Scaled Net Operating Assets (SNOA)(A: Dec. 2023 )
=(Operating Assets (A: Dec. 2023 )-Operating Liabilities (A: Dec. 2023 ))/Total Assets (A: Dec. 2022 )
=(97.244-40.893)/176.031
=0.32

where

Operating Assets(A: Dec. 2023 )
=Total Assets - Cash, Cash Equivalents, Marketable Securities
=180.369 - 83.125
=97.244

Operating Liabilities(A: Dec. 2023 )
=Total Liabilities - Long-Term Debt & Capital Lease Obligation - Short-Term Debt & Capital Lease Obligation
=126.599 - 82.258 - 3.448
=40.893

Akoya Biosciences's Scaled Net Operating Assets (SNOA) for the quarter that ended in Jun. 2024 is calculated as

Scaled Net Operating Assets (SNOA)(Q: Jun. 2024 )
=(Operating Assets (Q: Jun. 2024 )-Operating Liabilities (Q: Jun. 2024 ))/Total Assets (Q: Mar. 2024 )
=(98.521-36.798)/154.75
=0.40

where

Operating Assets(Q: Jun. 2024 )
=Total Assets - Cash, Cash Equivalents, Marketable Securities
=143.745 - 45.224
=98.521

Operating Liabilities(Q: Jun. 2024 )
=Total Liabilities - Long-Term Debt & Capital Lease Obligation - Short-Term Debt & Capital Lease Obligation
=121.496 - 81.376 - 3.322
=36.798

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Akoya Biosciences Scaled Net Operating Assets Related Terms

Thank you for viewing the detailed overview of Akoya Biosciences's Scaled Net Operating Assets provided by GuruFocus.com. Please click on the following links to see related term pages.


Akoya Biosciences Business Description

Traded in Other Exchanges
N/A
Address
100 Campus Drive, 6th Floor, Marlborough, MA, USA, 01752
Akoya Biosciences Inc is a life sciences technology company. It is delivering spatial biology solutions focused on transforming discovery, clinical research and diagnostics. Its PhenoCycler (formerly CODEX) and PhenoImager (formerly Phenoptics) platforms, reagents, software, and services, It offer end-to-end solutions to perform tissue analysis and spatial phenotyping across the full continuum from discovery through translational and clinical research and diagnostics.
Executives
Brian Mckelligon director, officer: President/CEO 100 CAMPUS DRIVE, 6TH FLOOR, MARLBOROUGH MA 01752
Frederic Pla officer: Chief Operating Officer C/O GENOMIC HEALTH, INC., 101 GALVESTON DRIVE, REDWOOD CITY CA 94063-4700
Goldman Myla Lai director 3595 JOHN HOPKINS COURT, SAN DIEGO CA 92121
John Frederick Ek officer: Chief Financial Officer 5964 LA PLACE COURT, CARLSBAD CA 92008
Scott Mendel director 5964 LA PLACE COURT, ADDRESS 2, CARLSBAD CA 92008
Matthew Winkler director C/O MIRNA THERAPEUTICS, INC., 2150 WOODWARD ST., SUITE 100, AUSTIN TX 78744
Thomas A. Raffin director, 10 percent owner C/O NEWLINK GENETICS CORP., 2503 SOUTH LOOP DR., SUITE 5100, AIMES IA 50010
Robert G Shepler director
Jennifer Kamocsay officer: General Counsel 100 CAMPUS DRIVE, 6TH FLOOR, MARLBOROUGH MA 01762
Joseph Driscoll officer: Chief Financial Officer 5 DICARLO ROAD, HOPKINTON MA 01748
Nolan Garry Ph.d. director 100 CAMPUS DRIVE, 6TH FLOOR, MARLBOROUGH MA 01752
Thomas P Schnettler director 800 NICOLLET MALL, J1012057, MINNEAPOLIS MN 55402-7020
Ehab El-gabry officer: Chief Medical Officer 100 CAMPUS DRIVE, 6TH FLOOR, MARLBOROUGH MA 01752
Marilee Moy officer: Chief People Officer 100 CAMPUS DRIVE, 6TH FLOOR, MARLBOROUGH MA 01752
Ramachandran Niro Ph.d officer: Chief Business Officer 100 CAMPUS DRIVE, 6TH FLOOR, MARLBOROUGH MA 01752